Novo Nordisk and Vivtex Corporation have entered into a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities.

Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist.

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy weight-loss drugs.

Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo Nordisk, in contrast, has been facing a lot of adversity ...

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up. Novo Nordisk's drug trial failure is the latest in a series of 2025 ...